This is a repository copy of Validation of Highly Sensitive Flow Cytometry as A Biomarker for Rituximab in SLE: A Rationale for More Intensive Treatment To Improve Clinical Outcomes.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/144371/

Version: Accepted Version

Proceedings Paper:

https://doi.org/10.1136/annrheumdis-2016-eular.5947

(c) 2016, Published by the BMJ Publishing Group Limited. This is an author produced version of an abstract published in Annals of the Rheumatic Diseases. Uploaded in accordance with the publisher's self-archiving policy.

Reuse
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
VALIDATION OF HIGHLY SENSITIVE FLOW CYTOMETRY AS A BIOMARKER FOR RITUXIMAB IN SLE: A RATIONALE FOR MORE INTENSIVE TREATMENT TO IMPROVE CLINICAL OUTCOMES

M. Y. Md Yusof 1, 2, D. Shaw1, A. Rawstron3, P. Emery1, 2, E. M. Vital1, 2
1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2Leeds Musculoskeletal Biomedical Research Unit, 3Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

My abstract has been or will be presented at a scientific meeting during a 12 months period prior to EULAR 2016: No

Is the first author applying for a travel bursary and/or an award for undergraduate medical students?: No

Background: Rituximab is effective for SLE in open label series however level of clinical response varies and was not superior to standard of care in randomised trials. We previously showed that clinical response was associated with the depth of initial B cell depletion and relapse was associated with early plasmablast repopulation[1].

Objectives: To validate B cell depletion as a predictor of response to rituximab in SLE as a basis to develop more effective B cell targeted therapy.

Methods: The published discovery cohort included 38 renal and extra-renal lupus patients. A validation cohort of 46 new patients was recruited. All patients received an initial cycle of 2 infusions of 1000mg rituximab, each preceded by 100mg methylprednisolone. Rituximab was repeated on clinical relapse. Concomitant therapy with cyclophosphamide was not used. Oral immunosuppressants were continued if used at baseline. Oral prednisolone doses varied. B cell depletion using a protocol optimized to detect low numbers of B cell subsets and plasmablasts was measured at baseline, after both infusions of rituximab (6 weeks) and at early B cell repopulation (6 months). Complete depletion was defined as total B cell count <0.0001 x 10^9/L.

Results: Depletion and response data were available for 84/100 patients. Overall complete depletion rate was 54%.

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Depletion</th>
<th>Non Response</th>
<th>Response</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discovery (n=38)</td>
<td>incomplete</td>
<td>7/22 (32%)</td>
<td>15/22 (68%)</td>
<td>0.012</td>
</tr>
<tr>
<td></td>
<td>Complete</td>
<td>0/16 (0%)</td>
<td>16/16 (100%)</td>
<td></td>
</tr>
<tr>
<td>Validation (n=46)</td>
<td>incomplete</td>
<td>5/17 (35%)</td>
<td>11/17 (65%)</td>
<td>0.014</td>
</tr>
<tr>
<td></td>
<td>Complete</td>
<td>2/29 (7%)</td>
<td>27/29 (93%)</td>
<td></td>
</tr>
<tr>
<td>Combined (n=84)</td>
<td>incomplete</td>
<td>13/39 (33%)</td>
<td>26/39 (67%)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>Complete</td>
<td>2/45 (4%)</td>
<td>43/45 (96%)</td>
<td></td>
</tr>
</tbody>
</table>

Incomplete depletion was predicted at baseline by low complement C4 (p=0.044) but not baseline BILAG score or immunosuppressant use. In original cohort there was a significant association between plasmablast repopulation (>0.0008x10^9/L) and time to relapse < 18 months (p=0.024). Follow up for relapse was limited to 22/36 responders in the validation cohort at the time of analysis, with a trend to the same association (p=0.119).

Conclusions: We have validated depth of B cell depletion as a predictor of response to rituximab in SLE. Clinical trials using more intensive rituximab treatment regimens, or alternative CD20 molecules are likely to increase clinical response rates to B cell depletion in clinical trials. B cell subsets should be monitored in the routine care of SLE patients receiving rituximab and repeat infusions considered if early depletion is incomplete or plasmablast repopulation is detected at 6 months.

Disclosure of Interest: M. Y. Md Yusof: None declared, D. Shaw: None declared, A. Rawstron: None declared, P. Emery Grant/research support from: Abbott, BMS, Pfizer, MSD and Roche., Consultant for: BMS, Abbott, Pfizer, MSD, Novartis, Roche and UCB, E. M. Vital: None declared